Doctor of Medicine, Chief Physician Long engaged in clinical and scientific research in oncology, with training at Memorial Sloan-Kettering Cancer Center in the United States. Possesses extensive clinical experience in malignant melanoma. Dedicated to the systemic treatment and management of complications in malignant melanoma and genitourinary system tumors (e.g., urothelial carcinoma, renal cell carcinoma, prostate cancer, germ cell tumors), as well as clinical diagnosis, scientific research, and talent cultivation. Pioneered the introduction of multiple internationally advanced therapeutic techniques in China and actively participated in the formulation and updating of Chinese diagnostic and treatment guidelines for melanoma, urothelial carcinoma, and renal cell carcinoma. Research findings have been published multiple times in prestigious domestic and international oncology journals such as JCO, CCR, and EJC, significantly advancing the level of melanoma and urologic tumor diagnosis and treatment in China and enhancing its international influence. Involved in numerous domestic and international clinical trials, serving as a key participant in the pre-marketing clinical study of China's first anti-PD-1 monoclonal antibody, Toripalimab. Holds multiple academic positions, including Chair of the Head and Neck Malignant Melanoma Professional Committee of the Beijing Cancer Prevention and Treatment Society, Member of the CSCO Melanoma Professional Committee, and Editorial Board Member of *Cancer Prevention and Treatment Research*. As a key participant, received the Third Prize of the Chinese Medical Science and Technology Award, the Second Prize of the Beijing Science and Technology Award, the Second Prize of the China Anti-Cancer Association Science and Technology Award, and the Third Prize of the Huaxia Medical Science and Technology Award.